|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18 Pt 1
|
|
pubmed:dateCreated |
2004-9-27
|
|
pubmed:abstractText |
Immunotherapy directed toward cell surface antigens may provide a novel approach to the eradication of chemoresistant micrometastatic disease in patients with small-cell lung cancer (SCLC). Studies in SCLC cell lines and human tissues suggest that the ganglioside fucosyl GM1 is an abundant yet specific target. A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AllenJennifer RJR,
pubmed-author:BaezValerieV,
pubmed-author:DanishefskySamuel JSJ,
pubmed-author:GomezJorgeJ,
pubmed-author:HoodChandraC,
pubmed-author:KedingStacy JSJ,
pubmed-author:KrisMark GMG,
pubmed-author:KrugLee MLM,
pubmed-author:LivingstonPhilip OPO,
pubmed-author:MillerVincent AVA,
pubmed-author:PizzoBarbaraB,
pubmed-author:RagupathiGovindG,
pubmed-author:TysonLeslieL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6094-100
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15447995-Adult,
pubmed-meshheading:15447995-Aged,
pubmed-meshheading:15447995-Aged, 80 and over,
pubmed-meshheading:15447995-Animals,
pubmed-meshheading:15447995-Antibodies, Neoplasm,
pubmed-meshheading:15447995-Cancer Vaccines,
pubmed-meshheading:15447995-Carbohydrate Sequence,
pubmed-meshheading:15447995-Carcinoma, Small Cell,
pubmed-meshheading:15447995-Cattle,
pubmed-meshheading:15447995-Cell Separation,
pubmed-meshheading:15447995-Chromatography, Thin Layer,
pubmed-meshheading:15447995-Complement System Proteins,
pubmed-meshheading:15447995-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15447995-Female,
pubmed-meshheading:15447995-Flow Cytometry,
pubmed-meshheading:15447995-G(M1) Ganglioside,
pubmed-meshheading:15447995-Hemocyanin,
pubmed-meshheading:15447995-Humans,
pubmed-meshheading:15447995-Immune Tolerance,
pubmed-meshheading:15447995-Immunoglobulin G,
pubmed-meshheading:15447995-Immunotherapy,
pubmed-meshheading:15447995-Lung Neoplasms,
pubmed-meshheading:15447995-Male,
pubmed-meshheading:15447995-Middle Aged,
pubmed-meshheading:15447995-Models, Chemical,
pubmed-meshheading:15447995-Molecular Sequence Data,
pubmed-meshheading:15447995-Time Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
|
|
pubmed:affiliation |
Thoracic Oncology Service, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. krugl@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
